What the FDA labels say about taking them together
Hydroxyurea and ivosidenib
Ivosidenib's FDA label of December 22, 2025 names hydroxyurea in its warnings and precautions section; the hydroxyurea labels PlainMeds reads (3) do not name ivosidenib.
Check it at the source: the hydroxyurea FDA label on DailyMed (effective September 15, 2025, Waylis Therapeutics LLC); the ivosidenib FDA label on DailyMed (effective December 22, 2025, Servier Pharmaceutical LLC).
What does the hydroxyurea label say about ivosidenib?
Hydroxyurea's label (effective September 15, 2025) and its 2 other brand-application labels do not name ivosidenib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (HYDREA), Waylis Therapeutics LLC, effective September 15, 2025 (SPL set 8d41152f-a98a-4abc-afdf-a909012434a0), via openFDA; the full label on DailyMed
What does the ivosidenib label say about hydroxyurea?
Ivosidenib label, warnings and precautionsSymptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid and/or hydroxyurea treatment.
Source: FDA drug label (TIBSOVO), Servier Pharmaceutical LLC, effective December 22, 2025 (SPL set 65d254c0-67ad-42c4-b972-ad463b755b2d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Hydroxyurea | Ivosidenib | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.184 per capsule 500 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once